Android app on Google Play

Bearish Analyst Comments on Dendreon (DNDN)

February 25, 2013 2:05 PM EST Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $2.09 -2.34%

Rating Summary:
    3 Buy, 18 Hold, 12 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 23 | New: 13
Trade DNDN Now!
Join SI Premium – FREE
Analysts at Brean Capital are negative on pharmaceutical company Dendreon Corp. (NASDAQ: DNDN) and today maintained a Sell rating on the stock with a price target of $2. Overall, analysts said they simply can't see how Dendreon can break even and they also expect the EMA to reject prostate cancer drug Provenge.

"Revenues from academic accounts declined 9% QoQ. We attribute this decline to academics as physicians that perhaps think a little bit more about the attributes of a drug before using it, rather than thinking about a 6% profit, and thus with Provenge's arguably questionable path to approval, these physicians clearly disfavor it," said analyst Jonathan Aschoff.

Brean Capital has a Sell rating on Dendreon price target of $2.00.

For an analyst ratings summary and ratings history on Dendreon (NASDAQ: DNDN) click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $5.67 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment